Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21918093 | 0.73 | HPGD (0.42) | HPGDTSHRLMNA | |
| SCHEMBL20682498 | 0.70 | HPGD (0.42) | HPGDTSHRLMNA | |
| SCHEMBL20730399 | 0.66 | ESR1 (0.40) | HPGDTSHRLMNA | |
| SCHEMBL23844586 | 0.65 | HCAR3 (0.46) | GPR84HCAR3 | |
| SCHEMBL29053956 | 0.62 | LMNA (0.42) | GPR84TSHRLMNA | |
| SCHEMBL22000611 | 0.61 | SMN1; SMN2 (0.42) | LMNA | |
| SCHEMBL14348299 | 0.60 | OPRM1 (0.42) | GPR84TSHRLMNA | |
| SCHEMBL5875341 | 0.60 | HDAC8 (0.44) | CNR2 | |
| SCHEMBL17696535 | 0.60 | CA12 (0.39) | HPGDTSHR | |
| SCHEMBL23861793 | 0.60 | HDAC8 (0.44) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TECHNISCHE UNIVERSITAT DORTMUND (DE) | 2021-08-03 | — | — | US | disclosed |
| US-20200123130-A1 | Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent | TECHNISCHE UNIVERSITAT DORTMUND (DE) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123130-A1 | Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent | TXNRD1, TXNRD3, TXNRD2 | GPR84 4288/4885HPGD 209/4885TSHR 660/4885 |
| US-11078185-B2 | Mycobacterium tuberculosis—thioredoxin reductase inhibitor as an antitubercular agent | TXNRD3, TXNRD1, TXN | GPR84 4354/4885HPGD 156/4885TSHR 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.